Strategy

Eurocan is focussed on becoming a global leader in the production of high quality, legally approved
cannabis products and extracts for medical use in a range of formulations

With innovation at our core, as rapid changes in legislation are opening up the European market, we are at the forefront of the fast growing legalised medicinal cannabis industry.

Governments across Europe are quickly responding to scientific research on the health benefits of legalised medicinal cannabis products.

According to analysis of current trends, Europe is set to become the world’s largest legal cannabis market over the next five years.

Eurocan's corporate strategy is aligned with projections of this growth and is pitched to become a global leader in the production of high quality, legally approved cannabis products for medical use.

58%

Expected growth


in legal cannabis spend (2019)

corporate-link-3

Corporate Strategy

operational-link-2

Operational Strategy


Corporate strategy


Grow value for all stakeholders


Complete licensing and application processes


Supplement board and advisory board


Construct world class operational facilities


Produce high quality products and sell through off take agreements


Take opportunity of the developing European market

Operational strategy


Operational strategy


  • Vertically integrated, operationally segmented supply chain
  • Northern and southern hemisphere growing operations will maximise yields and support consistent year-round yields harvests
  • European market access for sales through two EU operational hubs


Locations


Lesotho

Growing licence acquired (June 2019); preparations being made to commence operations and break ground

Malta

Application for permissions to undertake extraction submitted to Malta Enterprise (May 2019)

Portugal

AICEP application in process; land identified and terms being negotiated